BTTX - Better Therapeutics, Inc. Stock Price, Fair Value and News

Market Closed

BTTX Stock Valuation Analysis

Valuation

Max Portfolio %

BTTX Price Action

BTTX RSI Chart

BTTX Stock Valuation Analysis

Valuation

Max Portfolio %

BTTX Valuation

BTTX Price/Earnings (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BTTX Fundamentals

BTTX Earnings

BTTX Profitability

BTTX Investor Care

Revenue & Growth

About Better Therapeutics, Inc.

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

CEO	Mr. Frank L. Karbe
WEBSITE	bettertx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	54